These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18678823)

  • 21. Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy.
    Tsuji K; Furutama D; Tagami M; Ohsawa N
    Life Sci; 1999; 65(1):17-26. PubMed ID: 10403489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
    Nordmark G; Bengtsson C; Larsson A; Karlsson FA; Sturfelt G; Rönnblom L
    Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1.
    Tarnopolsky M; Mahoney D; Thompson T; Naylor H; Doherty TJ
    Muscle Nerve; 2004 Jan; 29(1):51-8. PubMed ID: 14694498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity.
    Callies F; Fassnacht M; van Vlijmen JC; Koehler I; Huebler D; Seibel MJ; Arlt W; Allolio B
    J Clin Endocrinol Metab; 2001 May; 86(5):1968-72. PubMed ID: 11344193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.
    Bassez G; Audureau E; Hogrel JY; Arrouasse R; Baghdoyan S; Bhugaloo H; Gourlay-Chu ML; Le Corvoisier P; Peschanski M
    Brain; 2018 Oct; 141(10):2855-2865. PubMed ID: 30169600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial.
    Rice SP; Agarwal N; Bolusani H; Newcombe R; Scanlon MF; Ludgate M; Rees DA
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1966-72. PubMed ID: 19318448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency.
    Yeung TW; Li RH; Lee VC; Ho PC; Ng EH
    J Clin Endocrinol Metab; 2013 Jan; 98(1):380-8. PubMed ID: 23144466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
    Schmidt PJ; Daly RC; Bloch M; Smith MJ; Danaceau MA; St Clair LS; Murphy JH; Haq N; Rubinow DR
    Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences.
    Bloch M; Meiboom H; Zaig I; Schreiber S; Abramov L
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):910-8. PubMed ID: 23084789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Heatwole C; Luebbe E; Rosero S; Eichinger K; Martens W; Hilbert J; Dekdebrun J; Dilek N; Zizzi C; Johnson N; Puwanant A; Tawil R; Schifitto G; Beck CA; Richeson JF; Zareba W; Thornton C; McDermott MP; Moxley R
    Neurology; 2021 Jan; 96(2):e228-e240. PubMed ID: 33046619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.
    Rabkin JG; Ferrando SJ; Wagner GJ; Rabkin R
    Psychoneuroendocrinology; 2000 Jan; 25(1):53-68. PubMed ID: 10633535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study.
    Orndahl G; Grimby G; Grimby A; Johansson G; Wilhelmsen L
    J Intern Med; 1994 Mar; 235(3):205-10. PubMed ID: 8120515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.
    Brooke AM; Kalingag LA; Miraki-Moud F; Camacho-Hübner C; Maher KT; Walker DM; Hinson JP; Monson JP
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):673-80. PubMed ID: 17054472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects.
    Danenberg HD; Ben-Yehuda A; Zakay-Rones Z; Gross DJ; Friedman G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2911-4. PubMed ID: 9284718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men.
    Wolf OT; Neumann O; Hellhammer DH; Geiben AC; Strasburger CJ; Dressendörfer RA; Pirke KM; Kirschbaum C
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2363-7. PubMed ID: 9215320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren's syndrome.
    Virkki LM; Porola P; Forsblad-d'Elia H; Valtysdottir S; Solovieva SA; Konttinen YT
    Arthritis Care Res (Hoboken); 2010 Jan; 62(1):118-24. PubMed ID: 20191499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ; Nolan JJ; Nelson JC; Yen SS
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency.
    Morales A; Black A; Emerson L; Barkin J; Kuzmarov I; Day A
    Aging Male; 2009 Dec; 12(4):104-12. PubMed ID: 19883295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.